Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors

Ziel

Protein aggregation is a major concern in biomedical research as this mechanism is responsible for at least 40 increasingly common human disorders, including Parkinson's disease, Alzheimer's disease, Huntington’s disease, Amyotrophic lateral sclerosis and certain types of cancer or type II diabetes. These protein aggregates can be isolated from patients in the form of amyloid depositions. Environmental conditions, such as pH, temperature, the interaction with other proteins, lipids or nucleic acids, the formation of phase-separated compartments or the presence of small molecules, influence the aggregation reaction. Until recently, the only available treatment for amyloidosis was palliative care. Fundamental research has identified small molecules from several hundred thousand different molecular entities and developed antibodies that delay amyloid conversion, leading to disease-modifying therapeutics for some of these pathologies. Yet prioritising the best candidates has led to overlooking the precise chemical and pharmacophoric determinants necessary to inhibit or delay aggregation for each protein variant. By manual curation of decades-long peer-reviewed knowledge, extraction and annotation of the effects of these multiple thousands of molecular entities, we will construct a database with aggregation-inhibiting and non-inhibiting molecules for each pathological protein. This data will be used to train a machine learning model that defines the chemical fingerprints required for preventing aggregation in each proteotype. The model will allow us to identify chemical entities not previously assayed, repurpose existing ones and design novel molecules. The most promising hits will be synthetised and experimentally assayed in vitro. Overall, this project represents a paradigm change to transition from the time and resource-costly trial-and-error screening toward a rational design of disease-modifying therapeutics.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-MSCA-2025-PF

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

VILNIAUS UNIVERSITETAS
Netto-EU-Beitrag
€ 196 976,16
Adresse
UNIVERSITETO G. 3
01513 Vilnius
Litauen
Region
Lietuva Sostinės regionas Vilniaus apskritis
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
Keine Daten